TIAA CREF Investment Management LLC purchased a new stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 67,237 shares of the biopharmaceutical company’s stock, valued at approximately $430,000. TIAA CREF Investment Management LLC owned about 0.17% of Abeona Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Geode Capital Management LLC boosted its position in Abeona Therapeutics by 2.4% during the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after acquiring an additional 4,588 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Abeona Therapeutics during the second quarter valued at $122,000. Bank of New York Mellon Corp boosted its position in Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 23,358 shares during the last quarter. Rhumbline Advisers bought a new stake in Abeona Therapeutics during the second quarter valued at $190,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Abeona Therapeutics during the second quarter valued at $264,000. 36.34% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Inc. (ABEO) opened at $15.40 on Monday. Abeona Therapeutics Inc. has a 1 year low of $4.05 and a 1 year high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities analysts predict that Abeona Therapeutics Inc. will post -0.7 earnings per share for the current year.
ABEO has been the topic of a number of research analyst reports. Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, August 24th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, October 6th. Citigroup Inc. initiated coverage on shares of Abeona Therapeutics in a research report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price target on the stock. Finally, BidaskClub cut shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.90.
Abeona Therapeutics Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc. (NASDAQ:ABEO).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.